Ray Co., Ltd. announced that it expects to receive KRW 25 billion in funding from KB Securities Co., Ltd., L&C Bio Co., Ltd, Samsung Securities Co., Ltd., Shinhan Investment & Securities Co., Ltd., NH Investment & Securities Co., Ltd., Hanwha Investment & Securities Co., Ltd.
March 24, 2024
Share
Ray Co., Ltd. announced a private placement of 2nd bearer interest unsecured private placement convertible bonds for the gross proceeds of KRW 25,000,000,000 on March 25, 2024. The bonds will be convertible into 1,483,327 common shares at a price of KRW 16,854 per share. The bonds have a zero coupon rate and will matured on March March 27, 2029.
The transaction has been approved by the shareholders of the company and is expected to close on March 27, 2024. The transaction will include participation from new investors, KB Securities Co., Ltd., L&C Bio Co., Ltd, Samsung Securities Co., Ltd., Shinhan Investment & Securities Co., Ltd., NH Investment & Securities Co., Ltd., Hanwha Investment & Securities Co., Ltd., JB Mezzanine New Technology Business Investment No. 2.
Ray Co.,Ltd is a Korea-based company mainly engaged in the development, production and distribution of dental imaging medical devices. Along with its subsidiaries, the Company manufactures and sells digital diagnostic systems and digital therapy solution products. Digital diagnostic systems include dental radiography equipments such as x-ray systems and cone beam computed tomography (CBCT) systems. Digital therapy solutions include three dimensional (3D) scanning, dental computer aided design (CAD), and 3D printers used in prosthodontics, orthodontics, and implant surgery. The Company distributes its products within domestic market and to overseas markets.
RAY CO., LTD. 
